The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine, also known as decitabine (Dacogen®/Otsuka America Pharmaceutical, Inc.) in combination with the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) can help to control Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). The safety of this drug combination will also be studied.
This trial is sponsored by M.D. Anderson Cancer Center. 
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Phase: II
- Enrollment: 71
- Start: February 2008
- Completion: August 2012
- Last verified: February 2013
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.